Late recurrences in long-term survivors of germ cell neoplasms

M. J. DeLeo, F. A. Greco, J. D. Hainsworth, D. H. Johnson

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

Patients with germ cell neoplasms who are in complete remission 2 years after treatment have a very high probability of cure, and reports of recurrences occurring after 2 years are rare. Of 81 testicular cancer patients treated for advanced disease at Vanderbilt University between 1970 and 1985, five developed a recurrent or metachronous germinal tumor 58 to 195 months after the initial treatment. Only two of these patients had received prior cisplatin-based combination chemotherapy. Four patients had unfavourable prognostic features when tumor recurrence was diagnosed. All five patients responded to salvage chemotherapy, although there were only two complete responses. The extent of disease was a significant factor in predicting response to salvage therapy. The possible mechanisms of development of a late recurrence of germinal neoplasms include the following: (1) malignant degeneration of mature teratoma to germinal malignancy; (2) growth of an occult testicular tumor not eliminated by chemotherapy due to the pressure of a blood-testicular barrier; (3) development of a second primary germ cell neoplasm; or (4) late relapse due to persistent microscopic viable tumor with an atypical less aggressive biologic behavior. 'Cured' germ cell tumor patients need careful follow-up beyond 2 years. At a minimum, these patients should be seen annually. Patients found to have teratomas following cisplatin-based chemotherapy should probably undergo more frequent evaluations.

Original languageEnglish (US)
Pages (from-to)985-988
Number of pages4
JournalCancer
Volume62
Issue number5
StatePublished - 1988

Fingerprint

Germ Cell and Embryonal Neoplasms
Survivors
Recurrence
Teratoma
Testicular Neoplasms
Neoplasms
Drug Therapy
Cisplatin
Salvage Therapy
Combination Drug Therapy
Blood Pressure
Therapeutics
Growth

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

DeLeo, M. J., Greco, F. A., Hainsworth, J. D., & Johnson, D. H. (1988). Late recurrences in long-term survivors of germ cell neoplasms. Cancer, 62(5), 985-988.

Late recurrences in long-term survivors of germ cell neoplasms. / DeLeo, M. J.; Greco, F. A.; Hainsworth, J. D.; Johnson, D. H.

In: Cancer, Vol. 62, No. 5, 1988, p. 985-988.

Research output: Contribution to journalArticle

DeLeo, MJ, Greco, FA, Hainsworth, JD & Johnson, DH 1988, 'Late recurrences in long-term survivors of germ cell neoplasms', Cancer, vol. 62, no. 5, pp. 985-988.
DeLeo MJ, Greco FA, Hainsworth JD, Johnson DH. Late recurrences in long-term survivors of germ cell neoplasms. Cancer. 1988;62(5):985-988.
DeLeo, M. J. ; Greco, F. A. ; Hainsworth, J. D. ; Johnson, D. H. / Late recurrences in long-term survivors of germ cell neoplasms. In: Cancer. 1988 ; Vol. 62, No. 5. pp. 985-988.
@article{9ed85ab139ef4259bf59ade10054cde1,
title = "Late recurrences in long-term survivors of germ cell neoplasms",
abstract = "Patients with germ cell neoplasms who are in complete remission 2 years after treatment have a very high probability of cure, and reports of recurrences occurring after 2 years are rare. Of 81 testicular cancer patients treated for advanced disease at Vanderbilt University between 1970 and 1985, five developed a recurrent or metachronous germinal tumor 58 to 195 months after the initial treatment. Only two of these patients had received prior cisplatin-based combination chemotherapy. Four patients had unfavourable prognostic features when tumor recurrence was diagnosed. All five patients responded to salvage chemotherapy, although there were only two complete responses. The extent of disease was a significant factor in predicting response to salvage therapy. The possible mechanisms of development of a late recurrence of germinal neoplasms include the following: (1) malignant degeneration of mature teratoma to germinal malignancy; (2) growth of an occult testicular tumor not eliminated by chemotherapy due to the pressure of a blood-testicular barrier; (3) development of a second primary germ cell neoplasm; or (4) late relapse due to persistent microscopic viable tumor with an atypical less aggressive biologic behavior. 'Cured' germ cell tumor patients need careful follow-up beyond 2 years. At a minimum, these patients should be seen annually. Patients found to have teratomas following cisplatin-based chemotherapy should probably undergo more frequent evaluations.",
author = "DeLeo, {M. J.} and Greco, {F. A.} and Hainsworth, {J. D.} and Johnson, {D. H.}",
year = "1988",
language = "English (US)",
volume = "62",
pages = "985--988",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "5",

}

TY - JOUR

T1 - Late recurrences in long-term survivors of germ cell neoplasms

AU - DeLeo, M. J.

AU - Greco, F. A.

AU - Hainsworth, J. D.

AU - Johnson, D. H.

PY - 1988

Y1 - 1988

N2 - Patients with germ cell neoplasms who are in complete remission 2 years after treatment have a very high probability of cure, and reports of recurrences occurring after 2 years are rare. Of 81 testicular cancer patients treated for advanced disease at Vanderbilt University between 1970 and 1985, five developed a recurrent or metachronous germinal tumor 58 to 195 months after the initial treatment. Only two of these patients had received prior cisplatin-based combination chemotherapy. Four patients had unfavourable prognostic features when tumor recurrence was diagnosed. All five patients responded to salvage chemotherapy, although there were only two complete responses. The extent of disease was a significant factor in predicting response to salvage therapy. The possible mechanisms of development of a late recurrence of germinal neoplasms include the following: (1) malignant degeneration of mature teratoma to germinal malignancy; (2) growth of an occult testicular tumor not eliminated by chemotherapy due to the pressure of a blood-testicular barrier; (3) development of a second primary germ cell neoplasm; or (4) late relapse due to persistent microscopic viable tumor with an atypical less aggressive biologic behavior. 'Cured' germ cell tumor patients need careful follow-up beyond 2 years. At a minimum, these patients should be seen annually. Patients found to have teratomas following cisplatin-based chemotherapy should probably undergo more frequent evaluations.

AB - Patients with germ cell neoplasms who are in complete remission 2 years after treatment have a very high probability of cure, and reports of recurrences occurring after 2 years are rare. Of 81 testicular cancer patients treated for advanced disease at Vanderbilt University between 1970 and 1985, five developed a recurrent or metachronous germinal tumor 58 to 195 months after the initial treatment. Only two of these patients had received prior cisplatin-based combination chemotherapy. Four patients had unfavourable prognostic features when tumor recurrence was diagnosed. All five patients responded to salvage chemotherapy, although there were only two complete responses. The extent of disease was a significant factor in predicting response to salvage therapy. The possible mechanisms of development of a late recurrence of germinal neoplasms include the following: (1) malignant degeneration of mature teratoma to germinal malignancy; (2) growth of an occult testicular tumor not eliminated by chemotherapy due to the pressure of a blood-testicular barrier; (3) development of a second primary germ cell neoplasm; or (4) late relapse due to persistent microscopic viable tumor with an atypical less aggressive biologic behavior. 'Cured' germ cell tumor patients need careful follow-up beyond 2 years. At a minimum, these patients should be seen annually. Patients found to have teratomas following cisplatin-based chemotherapy should probably undergo more frequent evaluations.

UR - http://www.scopus.com/inward/record.url?scp=0023761095&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023761095&partnerID=8YFLogxK

M3 - Article

VL - 62

SP - 985

EP - 988

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 5

ER -